MEDICINAL CHEMISTRY OF NOVEL ANTITHROMBOTIC DRUGS
新型抗血栓药物的药物化学
基本信息
- 批准号:3347148
- 负责人:
- 金额:$ 18.06万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1985
- 资助国家:美国
- 起止时间:1985-09-01 至 1995-06-30
- 项目状态:已结题
- 来源:
- 关键词:anticoagulants calcium chemical structure function diterpenes drug design /synthesis /production enzyme induction /repression heart function hormone regulation /control mechanism macrolide antibiotics neurotransmitters phosphatidylinositols phosphatidylserines platelet aggregation protein kinase C stereochemistry
项目摘要
Protein kinase C (PKC) is an important regulatory enzyme whose
physiological activation requires it to become membrane-bound. This occurs
via the simultaneous presence of calcium, an acidic phospholipid such as
phosphatidyl serine (PS), and a diglyceride. The presence of the latter is
of great regulatory significance because it is the product of
polyphosphatidylinositol turnover. The diglyceride requirement can be
satisfied by structurally diverse tumor promoters such as the phorbol
esters, teleocidin, and the debromoaplysiatoxins. It is likely that PKC is
an important target for the tumor promoters. In addition, PKC plays an
important role in platelet aggregation, cardiac function, and neural
function. The major focus of this grant is to understand the mechanism of
the novel activation process of PKC. Of particular interest is the
unravelling the structural basis for PKC activator function. On the one
hand, PKC is exceedingly selective with respect to the chemical structure
of diglyceride activators. At the same time, structurally diverse tumor
promoters belonging to the diterpene, peptide, and macrolide series , can
all potently activate the enzyme. These observations are reconciled here
with the presentation of a new unifying structural hypothesis on PKC
activators which are based on experiments described in the progress report.
This new hypothesis makes predictions concerning novel diglyceride and
peptide analogs which should potently interact with the kinase. These
molecules will be synthesized and studied as putative PKC activators and
inhibitors. Finally, novel cyclic PS analogs will be prepared to study the
specificity of the phospholipid binding-site of PKC.
Complimentary studies on the nature of activator binding-site are also
anticipated. The PKC regulatory domain binding-site will be covalently
labeled with activator-based photoaffinity probes and the labeled region
will be sequenced.
Taken together, these studies should bring us closer to an understanding of
the regulation of PKC at a molecular level and the general issue of how
proteins can interact with and bind to membranes. Finally, the structural
information obtained here will serve to map the PKC diglyceride
binding-site and can be used as a starting point to prepare potent
inhibitors of the enzyme.
蛋白激酶C(PKC)是一种重要的调节酶,其
生理激活需要它成为膜结合的。这种情况会发生
通过同时存在钙,一种酸性磷脂,如
磷脂酰丝氨酸(PS)和二甘油酯。后者的存在是
具有重要的监管意义,因为它是
聚磷脂酰肌醇周转率。甘油二酯的要求可以是
满足于结构多样化的肿瘤促进剂,如佛波醇
酯、刺青素和去溴青霉毒素。PKC很可能是
是肿瘤促进者的重要靶点。此外,PKC还扮演着一个
在血小板聚集、心功能和神经中的重要作用
功能。这笔赠款的主要重点是了解
PKC的新激活过程。特别值得关注的是
解开PKC激活子功能的结构基础。一对一
另一方面,PKC在化学结构方面具有极高的选择性
甘油二酯激活剂。同时,结构多样化的肿瘤
属于二萜、多肽和大环内酯类系列的启动子可以
它们都能有效地激活这种酶。这些观察结果在这里是一致的
提出了一个新的关于PKC的统一结构假说
基于进度报告中描述的实验的激活剂。
这一新的假说预测了新的双甘油三酯和
应与该激酶有效相互作用的多肽类似物。这些
分子将被合成并研究为可能的PKC激活剂和
抑制剂。最后,将制备新的环状PS类似物来研究
蛋白激酶C磷脂结合部位的特异性。
关于激活剂结合位点的性质的免费研究也在
已经预料到了。PKC调节结构域结合位点将是共价的
以激活剂为基础的光亲和探针标记以及标记区域
将被测序。
综上所述,这些研究应该会让我们更接近于了解
PKC在分子水平上的调控以及如何调控的一般问题
蛋白质可以与膜相互作用,并与膜结合。最后,结构性的
在这里获得的信息将有助于绘制PKC二甘油酯的图谱
结合部位,可作为制备强效物质的起点
酶的抑制剂。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ROBERT R RANDO其他文献
ROBERT R RANDO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ROBERT R RANDO', 18)}}的其他基金
Retinyl Ester Binding Proteins and the Visual Cycle
视黄酯结合蛋白和视觉周期
- 批准号:
7001202 - 财政年份:2005
- 资助金额:
$ 18.06万 - 项目类别:
Retinyl Ester Binding Proteins and the Visual Cycle
视黄酯结合蛋白和视觉周期
- 批准号:
6855567 - 财政年份:2005
- 资助金额:
$ 18.06万 - 项目类别:
Retinyl Ester Binding Proteins and the Visual Cycle
视黄酯结合蛋白和视觉周期
- 批准号:
7176097 - 财政年份:2005
- 资助金额:
$ 18.06万 - 项目类别:
AMINOGLYCOSIDE/RNA INTERACTIONS AND CORNEAL INFECTIONS
氨基糖苷/RNA 相互作用和角膜感染
- 批准号:
6476401 - 财政年份:1998
- 资助金额:
$ 18.06万 - 项目类别:
AMINOGLYCOSIDE/RNA INTERACTIONS AND CORNEAL INFECTIONS
氨基糖苷/RNA 相互作用和角膜感染
- 批准号:
6625011 - 财政年份:1998
- 资助金额:
$ 18.06万 - 项目类别:
AMINOGLYCOSIDE/RNA INTERACTIONS AND CORNEAL INFECTIONS
氨基糖苷/RNA 相互作用和角膜感染
- 批准号:
6329574 - 财政年份:1998
- 资助金额:
$ 18.06万 - 项目类别:
AMINOGLYCOSIDE/RNA INTERACTIONS AND CORNEAL INFECTIONS
氨基糖苷/RNA 相互作用和角膜感染
- 批准号:
6125153 - 财政年份:1998
- 资助金额:
$ 18.06万 - 项目类别:
AMINOGLYCOSIDE/RNA INTERACTIONS AND CORNEAL INFECTIONS
氨基糖苷/RNA 相互作用和角膜感染
- 批准号:
2739207 - 财政年份:1998
- 资助金额:
$ 18.06万 - 项目类别:
MEDICINAL CHEMISTRY OF NOVEL ANTITHROMBOTIC DRUGS
新型抗血栓药物的药物化学
- 批准号:
3347146 - 财政年份:1985
- 资助金额:
$ 18.06万 - 项目类别:
MEDICINAL CHEMISTRY OF NOVEL ANTITHROMBOTIC DRUGS
新型抗血栓药物的药物化学
- 批准号:
3347153 - 财政年份:1985
- 资助金额:
$ 18.06万 - 项目类别:
相似国自然基金
Calcium/NFAT/GLUT3通路调控糖酵解代谢在CAR-T细胞耗竭中的作用和机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
miR-30调控Calcium/Calcineurin通路在慢性肾脏病心肌保护中的作用
- 批准号:81670699
- 批准年份:2016
- 资助金额:58.0 万元
- 项目类别:面上项目
水稻OsCAS(Calcium-sensing Receptor)基因的功能分析
- 批准号:30900771
- 批准年份:2009
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
相似海外基金
zero-CO2 cemeNt ThRough cArBonation of cAlcium Silicates and aluminateS (Contrabass)
通过硅酸钙和铝酸盐的碳化生产零二氧化碳水泥(Contrabass)
- 批准号:
EP/Y030354/1 - 财政年份:2024
- 资助金额:
$ 18.06万 - 项目类别:
Research Grant
CONTRABASS - zero-CO2 cemeNt ThRough cArBonation of cAlcium Silicates and aluminateS
CONTRABASS - 通过硅酸钙和铝酸盐碳化生产的零二氧化碳水泥
- 批准号:
EP/Y031989/1 - 财政年份:2024
- 资助金额:
$ 18.06万 - 项目类别:
Research Grant
NSF Convergence Accelerator Track M: A new biomanufacturing process for making precipitated calcium carbonate and plant-based compounds that support human health
NSF Convergence Accelerator Track M:一种新的生物制造工艺,用于制造支持人类健康的沉淀碳酸钙和植物基化合物
- 批准号:
2344228 - 财政年份:2024
- 资助金额:
$ 18.06万 - 项目类别:
Standard Grant
DEL-1 Promotes Biogenesis of Mineralizing Extracellular Vesicles by Mediating Intracellular Calcium Signaling
DEL-1 通过介导细胞内钙信号传导促进矿化细胞外囊泡的生物合成
- 批准号:
24K19876 - 财政年份:2024
- 资助金额:
$ 18.06万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The development of targeterd therapies for Intra-mitochondrial calcium ion dinamics in colorectal cancer stem cells
结直肠癌干细胞线粒体内钙离子动态靶向疗法的开发
- 批准号:
23K06654 - 财政年份:2023
- 资助金额:
$ 18.06万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Muscle contraction and calcium signaling
肌肉收缩和钙信号传导
- 批准号:
23K10634 - 财政年份:2023
- 资助金额:
$ 18.06万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
RUI: Allosteric Activators of the Sarco/Endoplasmic Reticulum Calcium ATPase
RUI:肌瘤/内质网钙 ATP 酶的变构激活剂
- 批准号:
2327946 - 财政年份:2023
- 资助金额:
$ 18.06万 - 项目类别:
Standard Grant
Understanding the cellular response to calcium influx based on endoplasmic reticulum-mitochondria interaction
基于内质网-线粒体相互作用了解细胞对钙流入的反应
- 批准号:
22KJ3086 - 财政年份:2023
- 资助金额:
$ 18.06万 - 项目类别:
Grant-in-Aid for JSPS Fellows
In vivo calcium imaging during appetitive learning in HIV Tat transgenic mice exposed to cannabis
暴露于大麻的 HIV Tat 转基因小鼠食欲学习过程中的体内钙成像
- 批准号:
10696442 - 财政年份:2023
- 资助金额:
$ 18.06万 - 项目类别:














{{item.name}}会员




